| T12/PR48 | T12 (DS)/PR48 | Pbo/PR48 | |
| % | Relapsers | ||
| N=145 | N=141 | N=68 | |
| SVR** (p value*) | 83 (<0.001) | 88 (<0.001) | 24 |
| Prior PR Non-responders | |||
| N=121 | N=123 | N=64 | |
| SVR** (p value*) | 41 (<0.001) | 42 (<0.001) | 9 |
| Partial-responders | |||
| N=49 | N=48 | N=27 | |
| SVR** (p value*) | 59 (<0.001) | 54 (<0.001) | 15 |
| Prior PR null-responders (<2 log decline in HCV RNA at wk 12 of prior therapy) | |||
| N=72 | N=75 | N=37 | |
| SVR** (p value*) | 29 (<0.001) | 33 (<0.001) | 5 |
* In comparison to Pbo/PR48.
** Assessed 24 weeks after planned treatment completion.